Aptevo Therapeutics AI Stock Analysis
Want to see APVO full AI Analyst Report?
Aptevo Therapeutics (APVO) AI Stock Analysis
Aptevo Therapeutics
(NASDAQ:APVO)
The score is held down primarily by weak financial performance (no revenue, large recurring losses, and heavy cash burn) and very bearish technicals (price far below moving averages with negative momentum). Corporate events provide some offset via positive clinical/pipeline updates and incremental funding, but valuation support is limited given negative earnings and no dividend.
Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 113.17K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.32
- Revenue Growth
- ―
- EPS Growth
- 99.31%
- Country
- US
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Aptevo Therapeutics Business Overview & Revenue Model
Company Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antib...
Aptevo Therapeutics Financial Statement Overview
Summary
Financial statements indicate very high operating risk: no revenue reported, large and persistent net losses (~$26M TTM), and substantial ongoing cash burn (operating cash flow about -$25M TTM). Debt is not extreme, but equity volatility and deeply negative ROE point to fragile capital stability and elevated dilution/financing risk.
Income Statement
9Very NegativeBalance Sheet
33NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 3.11M | 12.29M |
| Gross Profit | -116.00K | -240.00K | -352.00K | 0 | 3.11M | 12.29M |
| EBITDA | -26.39M | -25.73M | -23.78M | -18.08M | 7.92M | -28.26M |
| Net Income | -26.41M | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
Balance Sheet | ||||||
| Total Assets | 14.52M | 27.19M | 15.59M | 24.84M | 34.22M | 56.60M |
| Cash, Cash Equivalents and Short-Term Investments | 9.80M | 21.62M | 8.71M | 16.90M | 22.64M | 45.04M |
| Total Debt | 4.21M | 4.63M | 4.63M | 5.40M | 9.54M | 16.71M |
| Total Liabilities | 8.48M | 9.81M | 10.84M | 12.62M | 16.24M | 55.38M |
| Stockholders Equity | 6.04M | 17.38M | 4.75M | 12.22M | 17.97M | 1.22M |
Cash Flow | ||||||
| Free Cash Flow | -25.34M | -25.59M | -23.79M | -11.73M | -21.05M | -22.39M |
| Operating Cash Flow | -25.34M | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -29.00K | -713.00K |
| Financing Cash Flow | 25.73M | 38.50M | 15.60M | 6.00M | -2.62M | 26.16M |
Aptevo Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.57, and below the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 10.75 is Positive, neither overbought nor oversold. The STOCH value of 0.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.
Aptevo Therapeutics Risk Analysis
Aptevo Therapeutics disclosed 58 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskAptevo Therapeutics Peers Comparison
Overall Rating
LSTA49Neutral
ALLR44Neutral
MBRX44Neutral
APVO41Neutral
EDSA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $11.78M | -0.60 | -164.72% | ― | -90.65% | 11.37% | |
| 44Neutral | $14.00M | -0.89 | -349.08% | ― | ― | 38.64% | |
| 44Neutral | $7.58M | -0.64 | -81.19% | ― | ― | 99.02% | |
| 41Neutral | $993.08K | -0.00 | -290.07% | ― | ― | 99.31% | |
| 40Underperform | $25.54M | -1.15 | -124.21% | ― | ― | -27.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| APVO | Aptevo | 0.55 | -23.21 | -97.69% | |
| LSTA | Lisata Therapeutics, Inc. | 1.09 | -0.96 | -46.83% | |
| MBRX | Moleculin Biotech | 7.14 | -202.86 | -96.60% | |
| EDSA | Edesa Biotech | 1.89 | 0.15 | 8.62% | |
| ALLR | Allarity Therapeutics, Inc. | 0.88 | -0.26 | -23.25% |
Aptevo Therapeutics Corporate Events
Aptevo Therapeutics Announces Warrant Exercise Financing Agreement
PositiveOn November 11, 2026, Aptevo entered agreements with certain warrant holders who agreed to exercise existing warrants for up to 2,777,778 shares at a reduced price of $1.08 per share. The transaction closed on November 12, 2026, and the company recei...
Aptevo Presents New Multispecific Immunotherapy Data at SITC 2026
PositiveOn November 7, 2026, Aptevo presented new preclinical data from its next-generation multispecific platform at SITC 2026, showing that APVO451 and APVO452 promoted cancer-cell killing and T-cell activation under immunosuppressive conditions. The data...
Aptevo Reports Improved Mipletamig Tolerability in Frontline AML
PositiveOn November 5, 2026, Aptevo announced that successive refinements to mipletamig’s priming-dose regimen substantially reduced infusion-related reactions in frontline AML. The improvement built on the candidate’s favorable safety and tolerability profi...
Aptevo highlights promising AML transplant outcomes with mipletamig
PositiveOn October 26, 2026, Aptevo reported that ten of forty-seven frontline acute myeloid leukemia patients initially considered unfit for intensive chemotherapy advanced to allogeneic stem cell transplant after treatment with mipletamig plus venetoclax a...
Aptevo Therapeutics Reports New Material Definitive Agreement
NeutralIn a recent filing, Aptevo Therapeutics reported that information related to its entry into a material definitive agreement has been cross-referenced within its current report on Form 8-K. The disclosure indicates that key terms of the agreement are...
Aptevo to Present CD40 Multispecific Cancer Platform
PositiveOn October 14, 2026, Aptevo Therapeutics announced plans to showcase its multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting, scheduled for November 4–8, 2026, in Phoenix, Arizona. The presentation will highlight Apt...
Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs
PositiveOn September 24, 2026, Aptevo Therapeutics announced it is advancing its next-generation trispecific immuno-oncology programs, optimizing several candidates for reliable, scalable manufacturing. The company’s lead trispecific candidate, APVO451, is b...
Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes
PositiveOn September 22, 2026, Aptevo Therapeutics stockholders held a special meeting at which they rejected proposed technical and administrative amendments to the company’s Amended and Restated Certificate of Incorporation, despite a majority of votes cas...
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML
PositiveOn September 3, 2026, Aptevo Therapeutics reported new data showing a 93% clinical benefit rate for its lead drug candidate mipletamig, used in combination with venetoclax and azacitidine, in 14 evaluable frontline acute myeloid leukemia patients wit...
Aptevo Shareholders Back Board, Auditor and Incentive Plan
PositiveOn August 21, 2026, Aptevo Therapeutics Inc. held its Annual Meeting of Stockholders, at which shareholders elected Zsolt Harsanyi, Ph.D., and Barbara Lopez Kunz to the board to serve until the 2029 annual meeting, and ratified Baker Tilly US, LLP as...
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing
NeutralOn August 12, 2026, Aptevo Therapeutics entered into warrant inducement agreements and a securities purchase agreement with certain existing warrant holders, leading to the exercise of prior warrants at a reduced price of $4.03 per share and the issu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
